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Abstract
Introduction: Scleroderma or systemic sclerosis (SSc) is a complex connective tissue disease characterized by
fibrosis of skin and internal organs. Transforming growth factor beta (TGF-b) plays a key role in the pathogenesis of
SSc fibrosis. We have previously identified CD109 as a novel TGF-b co-receptor that inhibits TGF-b signaling. The
aim of the present study was to determine the role of CD109 in regulating extracellular matrix (ECM) production in
human SSc skin fibroblasts.
Methods: CD109 expression was determined in skin tissue and cultured skin fibroblasts of SSc patients and normal
healthy subjects, using immunofluorescence, western blot and RT-PCR. The effect of CD109 on ECM synthesis was
determined by blocking CD109 expression using CD109-specific siRNA or addition of recombinant CD109 protein,
and analyzing the expression of ECM components by western blot.
Results: The expression of CD109 proteinis markedly increased in SSc skin tissue in vivo and in SSc skin fibroblasts
in vitro as compared to their normal counterparts. Importantly, both SSc and normal skin fibroblasts transfected
with CD109-specific siRNA display increased fibronectin, collagen type I and CCN2 protein levels and enhanced
Smad2/3 phosphorylation compared with control siRNA transfectants. Furthermore, addition of recombinant CD109
protein decreases TGF-b1-induced fibronectin, collagen type I and CCN2 levels in SSc and normal fibroblasts.
Conclusion: The upregulation of CD109 protein in SSc may represent an adaptation or consequence of aberrant
TGF-b signaling in SSc. Our finding that CD109 is able to decrease excessive ECM production in SSc fibroblasts
suggest that this molecule has potential therapeutic value for the treatment of SSc.
Introduction
Scleroderma or systemic sclerosis (SSc) is a complex
connective tissue disorder characterized by autoimmu-
nity, vasculopathy and progressive fibrosis of skin and
internal organs [1-3]. SSc is commonly classified into
two major clinical subsets, diffuse SSc and limited SSc,
based largely on the degree of skin involvement [4].
Although there are a number of disease characteristics
that differentiate between these two groups, both share
the common clinical hallmark of fibrosis - characterized
by excessive extracellular matrix (ECM) production,
leading to disruption of normal tissue architecture and
eventually organ failure [5]. Although much progress
has been made in understanding the molecular mechan-
isms underlying the pathophysiology of SSc [2,6,7], there
are currently no therapies to halt the fibrotic process or
to slow progression of the disease [5,8,9].
Transforming growth factor beta (TGF-b) is a multi-
functional cytokine that regulates cell proliferation, cell
differentiation and ECM production [10-12]. TGF-b is
the most potent profibrotic cytokine known and
is thought to play a key role in SSc pathogenesis
[2,6,13,14]. Cultured SSc fibroblasts display constitu-
tively elevated ECM synthesis, which has been attributed
to aberrant activation of autocrine TGF-b signaling
[15,16]. Some studies have demonstrated increased
TGF-b receptor levels in SSc fibroblasts [17-19] that
might contribute to activation of autocrine TGF-b sig-
naling [16]. However, these findings have not been
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universally reproduced [20,21], emphasizing the need for
further investigation.
TGF-b signaling is transduced by a pair of transmem-
brane serine/threonine kinases known as the TGF-b
type I and type II receptors [22]. TGF-b binds the TGF-
b type II receptor, which then recruits and phosphory-
lates the TGF-b type I receptor resulting in activation of
TGF-b type I receptor kinase activity [23,24]. The TGF-
b type I receptor propagates the signal by phosphorylat-
ing intracellular Smad2 and Smad3 proteins, which form
a complex with Smad4. The Smad complexes then
translocate to the nucleus where they interact with var-
ious co-activators, co-repressors and transcription fac-
tors to regulate target gene expression [12,25,26].
Important TGF-b target genes relevant to fibrotic pro-
gression in SSc include ECM proteins such as fibronec-
tin and collagen type I and the matricellular protein
CCN2 [2,27].
CD109 is a 180 kDa glycosylphosphatidylinositol-
anchored protein belonging to the a2-macroglobulin/
complement superfamily [28,29]. Although CD109 is
expressed in a variety of cell types and its expression is
altered in many types of cancer, the function of this
protein is poorly understood [28-35]. We have recently
identified CD109 as a TGF-b co-receptor and inhibitor
of TGF-b signaling in human keratinocytes [36,37]. The
purpose of the current study was to determine whether
CD109 expression is altered in SSc skin and whether
CD109 may decrease the uncontrolled production of
ECM proteins by SSc skin fibroblasts.
Materials and methods
Human subjects
Nineteen patients diagnosed with SSc (17 females, two
males; Table 1) and nine normal healthy subjects (seven
females and two males aged 35 to 55 years) were stu-
died. Diagnosis of SSc was performed according to the
classification criteria of the American College of Rheu-
matology [38]. Punch biopsies were obtained from the
dorsal forearm of subjects with informed consent. Biop-
sies were divided into two parts, with one part placed in
10% buffered formalin for immunohistochemistry and
the other part in DMEM for fibroblast isolation. This
study was approved by the Institutional Review Com-
mittee of McGill University.
Cell isolation and culture
Biopsies were incubated in 0.5% dispase (Invitrogen,
Carlsbad, CA, USA) overnight at 4°C, and the dermis
was separated from the epidermis. The epidermis was
incubated with 0.25% trypsin (Invitrogen) for 20 minutes
and the released keratinocytes were cultured in kerati-
nocyte serum-free media (Invitrogen). The dermis was
incubated with 0.1% collagenase (Invitrogen) overnight
and the released fibroblasts were cultured in DMEM
containing 10% fetal bovine serum. Experiments were
performed using fibroblasts between passages 3 and 6.
Fibroblasts were serum-starved for 24 hours and treated
with TGF-b1 (Genzyme Corporation, Framingham, MA,
USA) without or with recombinant CD109 (R&D Sys-
tems Inc., Minneapolis, MN, USA). Cell lysates were
prepared and stored at -80°C until further analysis.
Immunohistochemistry
SSc and normal skin biopsies were fixed in formalin,
embedded in paraffin and cut into 4 μm serial sections
using a microtome. SSc and normal skin fibroblasts cul-
tured on glass coverslips were fixed with 4% paraformal-
dehyde. Tissue sections and cells were deparaffinized
and rehydrated, and antigen retrieval was performed by
heating at 95°C for 20 minutes in sodium citrate buffer
(10 mM, pH 8.5). The samples were then permeabilized
with PBS containing 0.1% Triton X-100. Blocking was
performed with 10% normal rabbit serum for 1 hour at
room temperature. Sections were then incubated with a
mouse anti-human CD109 antibody (R&D Systems Inc.)
overnight at 4°C, followed by an Alexa Fluor 488-conju-
gated rabbit anti-mouse secondary antibody (AF-488;
Invitrogen) for 2 hours at room temperature. Immuno-
fluorescent images were obtained using a fluorescence
microscope (Olympus B202; Carson Group Inc., Mark-
ham, ON, Canada) with a digital camera. Alternatively,
sections incubated with the anti-human CD109 antibody
as above were detected with a horseradish peroxidase-
conjugated rabbit anti-mouse secondary antibody fol-
lowed by diaminobenzidine staining.
Reverse transcription-polymerase chain reaction
Total RNA was extracted from SSc and normal skin
fibroblasts using the RNeasy Mini Kit (Qiagen, Missis-
sauga, ON, Canada) and reverse transcribed using
MMLV reverse transcriptase with oligo-dT as primer.
PCR was performed using CD109 (forward primer,
5’-GCCTTTGATTTAGATGTTGCTGTA-3’; reverse
primer, 5’-TATTCCACTTTCTTCACTGTCTCG-3’; pro-
duct length 188 bp) and GAPDH (forward primer, 5’-
GGGGAGCCAAAAGGGTCATCATCT-3’; and reverse
primer, 5’-TTGGCCAGGGGTGCTAAG-3’; product
length 145 bp) primers and Taq DNA polymerase (Invi-
trogen). After denaturation at 95°C for 5 minutes, the
reaction was performed for 25 cycles at 95°C for 30 sec-
onds, 59°C for 30 seconds and 72°C for 30 seconds. The
PCR products were separated in 1.5% agarose gel and
visualized by ethidium bromide staining.
Real-time PCR was performed using the Bio-Rad
CFX96 Real-Time System using the RT2 SYBR Green
qPCR Master Mix (Qiagen Inc., Mississauga, ON,
Canada) with CD109-specific primers (product size 147
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bp, catalogue number PPH10537A; SABiosciences) and
GAPDH-specific primers (forward primer, 5’-AAGAT-
CATCAGCAATGCCTCCTG-3’; and reverse primer, 5’-
TGACCTTGCCCACAGCCTT-3’; product length 228
bp). PCR was performed with an initial denaturation
step for 10 minutes at 95°C followed by 40 cycles at 95°
C for 15 seconds, 55°C for 30 seconds and 72°C for 30
seconds. Data were analyzed using the ΔCt method and
are presented as the fold-change in ΔCt.
siRNA transfection
SSc and normal skin fibroblasts were transfected with
CD109-specific siRNA (Stealth™; Invitrogen) or control
siRNA using the TransIT-LT1 transfection reagent (Mirus
Bio LLC, Madison, WI, USA). Cell lysates were prepared
48 hours later and were analyzed by western blot.
Western blot
Cell lysates were prepared in RIPA buffer (50 mM Tris-
HCl, 1% NP-40, 0.25% sodium deoxycholate, 150 mM
NaCl, 1 mM ethylenediamine tetraacetic acid, 1 mM
phenylmethylsulfonyl fluoride, 1 mM Na3VO4, 1 mM
NaF and Roche complete Protease Inhibitor Cocktail;
Roche Applied Biosciences, Laval, QC, Canada), and
protein concentrations were determined. Cell lysates (15
μg per lane) were separated by SDS-PAGE and trans-
ferred onto nitrocellulose membranes (Millipore, Bed-
ford, MA, USA). Following blocking with 5% nonfat dry
milk in Tris-buffered saline-Tween at room temperature
for 1 hour, membranes were incubated overnight with
antibodies against CD109 (R&D Systems Inc.), pSmad2,
pSmad3 and Smad2 (all from Cell Signaling Technology,
Danvers, MA, USA), collagen type I (Abcam, Cam-
bridge, MA, USA), fibronectin (BD Biosciences, Missis-
sauga, ON, Canada) and CCN2, Smad3 and b-actin (all
from Santa Cruz Biotechnology, Santa Cruz, CA, USA)
followed by incubation with a horseradish peroxidase-
conjugated secondary antibody. Immunoblots were
developed with enhanced-chemiluminescence reagents
(GE Healthcare, Baie d’Urfe, QC, Canada). Densito-
metric analysis was performed using Gel-Pro Analyzer
software V4.0 (Media Cybernetics, Bethesda, MD, USA)
and statistical analysis was performed by one-way analy-
sis of variance followed by an all-pairwise multiple com-
parison procedure (Holm-Sidak method) with an overall
significance level of 0.05.
Results
CD109 protein expression is increased in SSc skin
compared with normal skin in vivo
We have previously demonstrated that CD109 is
expressed in vitro in normal human keratinocytes
[37,39,40] and fibroblasts [41,42]. Here we examined
CD109 expression in SSc and normal skin tissue by
immunohistochemistry. Figure 1A shows that CD109
protein is detected in SSc skin (right panel) and normal
skin (left panel). Notably, the expression of CD109 pro-
tein is markedly increased in both the dermis and
Table 1 Patient information








S1 Female 49 1 Limited 2.93 1.15
S2 Female 62 9 Limited 4.72 0.53
S3 Female 56 6 Diffuse 5.46 0.37
S4 Female 76 10 Limited 8.87 0.74
S5 Female 53 2 Limited 2.38 0.89
S6 Female 63 5 Limited 11.54 1.02
S7 Female 58 33 Diffuse 1.51 0.65
S8 Female 51 31 Diffuse 13.63 0.92
S9 Female 66 4 Limited 5.62 1.39
S10 Female 45 41 Diffuse 5.62 0.29
S11 Female 55 29 Diffuse 12.60 0.58
S12 Female 53 2 Limited 2.45 1.28
S13 Female 70 7 Diffuse 17.45 2.42
S14 Female 68 10 Diffuse 5.68 1.47
S15 Female 63 2 Limited 28.87 0.35
S16 Male 69 4 Limited 1.66 1.45
S17 Male 77 2 Limited 13.46 ND
S18 Female 49 0 Limited 6.00 ND
S19 Female 60 1 Limited 23.75 ND
Modified Rodnan Skin Score from [54]. ND, not determined. aSee Figure 2A, B.
Man et al. Arthritis Research & Therapy 2012, 14:R144
http://arthritis-research.com/content/14/3/R144
Page 3 of 12
epidermis of SSc skin compared with those of normal
skin, as detected by a more intense immunofluorescent
signal using an Alexa Fluor 488-conjugated secondary
antibody (Figure 1A). Similar results were obtained by
immunostaining using a horseradish peroxidase-conju-
gated secondary antibody with diaminobenzidine as a
substrate (Figure 1B).
CD109 protein expression is increased in SSc skin cells
(fibroblasts and keratinocytes) compared with normal
skin cells in vitro
Fibroblasts are the main cell type responsible for exces-
sive ECM production in SSc [13], and cultured SSc
fibroblasts continue to express elevated ECM production
compared with normal fibroblasts [16]. We therefore
analyzed CD109 expression in cultured SSc and normal
skin fibroblasts, using immunofluorescence detection.
The results shown in Figure 1C demonstrate that
CD109 protein is detected in both SSc and normal skin
fibroblasts in culture and is localized to the plasma
membrane, with diffuse staining in the cytoplasm.
Although the cytoplasmic staining may represent newly
synthesized CD109 protein and/or CD109 protein that
has undergone internalization, the method used does
not allow us to precisely define the localization of
CD109 in these cells. Importantly, SSc skin fibroblasts
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Figure 1 CD109 protein expression is increased in systemic sclerosis skin and in cultured systemic sclerosis skin fibroblasts. (A, B)
Immunohistochemistry: systemic sclerosis (SSc) (Patients S1 and S19 in Table 1) and normal (controls N1 and N9) skin sections were analyzed by
immunohistochemistry using an anti-CD109 antibody followed by detection with (A) Alexa Fluor 488-conjugated secondary antibody (Patient S1
and control N1) or (B) horseradish peroxidase-conjugated secondary antibody (Patient S19 and control N9) followed by diaminobenzidine
staining, as described in Materials and methods. (C) Immunocytochemistry: SSc (Patient S1) and normal (control N1) skin fibroblasts were grown
in culture and were analyzed by immunocytochemistry using an anti-CD109 antibody followed by detection with an Alexa Fluor 488-conjugated
secondary antibody, as described in Materials and methods. Immunofluorescence microscopy was done using Olympus B202 (Carson Group Inc.,
Markham, ON, Canada). Images captured with a digital camera (DC-330; Dage-MTI Inc., Michigan City, IN, USA). Scale bar: 50 μM. Results
presented are representative of three independent experiments. (D, E) Western blot: cell lysates prepared from cultured SSc and normal
keratinocytes were analyzed by western blot using an anti-CD109 antibody. The membrane was reprobed with an anti-b-actin antibody to
confirm equal protein loading (D). Densitometric analysis of CD109 protein levels (180 kDa band) in the cell lysates of SSc (n = 6) and normal (n
= 6) keratinocytes was performed using b-actin as a loading control (P < 0.05).
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Because CD109 protein levels are also increased in SSc
epidermis compared with normal epidermis (Figure 1A,
B), we sought to determine CD109 protein expression in
cultured SSc and normal keratinocytes. Figure 1D shows
that CD109 protein levels are markedly increased in cell
lysates from SSc keratinocytes compared with normal
keratinocytes as determined by western blot (upper
panel). Reprobing the membrane with an anti-b-actin
antibody confirms that equal amounts of protein were
loaded in each lane. Densitometric analysis of CD109
protein levels (180 kDa band) in the cell lysates of SSc
keratinocytes (n = 6) and normal keratinocytes (n = 6)
was then performed using b-actin as a loading control.
The results indicate that SSc keratinocytes display signif-
icantly (P < 0.05) higher CD109 protein levels compared
with normal keratinocytes (Figure 1E).
Elevated CD109 protein expression is not associated with
an increase in CD109 mRNA expression in SSc skin
fibroblasts
The above results suggest that SSc fibroblasts express
higher levels of CD109 protein in vivo compared with
their normal counterparts and that SSc fibroblasts con-
tinue to express elevated CD109 protein in vitro. We
further examined CD109 protein expression in vitro in
SSc skin fibroblasts and normal skin fibroblasts by wes-
tern blot (Figure 2A). Results shown in Figure 2A
demonstrate that SSc skin fibroblasts show higher
CD109 protein levels compared with normal skin fibro-
blasts. Densitometric analysis of CD109 protein levels
(180 kDa band) in the cell lysates of SSc and normal
skin fibroblasts was then performed using b-actin as a
loading control. Results from two independent experi-
ments corresponding to skin fibroblasts from two differ-
ent randomly selected groups of SSc patients versus
normal subjects are shown in Figure 2B. Further analysis
of these data obtained from 16 SSc patients (nine with
limited SSc and seven with diffuse SSc) and nine normal
healthy controls was performed after reorganization into
normal control, limited SSc and diffuse SSc groups. One
data point (outlier) from the control group (value =
1.04) was removed. Determination of the fold-change in
the ratio of CD109/b-actin in the limited SSc and dif-
fuse SSc groups compared with normal controls shows
that both limited SSc and diffuse SSc skin fibroblasts
display significantly (P < 0.05) higher CD109 protein
levels compared with normal skin fibroblasts (Figure
2C).
We next determined CD109 mRNA expression in SSc
(n = 7) and normal (n = 7) skin fibroblasts by RT-PCR.
Figure 2D indicates that SSc and normal skin fibroblasts
display similar levels of CD109 mRNA expression (top
panel). RT-PCR of GAPDH indicates that similar
amounts of GAPDH are present in all samples (Figure
2D, bottom panel). Densitometric analysis of the data
shown in Figure 2D is presented in Figure 2E and indi-
cates that CD109/GAPDH levels in SSc and normal skin
fibroblasts are not significantly different (P = 0.717). We
further analyzed CD109 mRNA expression levels by
real-time RT-PCR in SSc (n = 4) and normal (n = 3)
skin fibroblasts and obtained similar results (data not
shown).
Treatment with exogenous TGF-b1 does not alter CD109
protein levels in SSc and normal skin fibroblasts
TGF-b is the most potent profibrotic cytokine known
and has been implicated in the pathogenesis of SSc
fibrosis [2,5]. Because our results indicate that CD109
protein levels are elevated in cultured SSc fibroblasts,
we sought to determine whether TGF-b regulates
CD109 protein levels. Figure 3 (top panel) shows that
CD109 protein levels are higher in SSc skin fibroblasts
compared with normal skin fibroblasts in the absence of
TGF-b treatment (lane 1 vs. lane 7), as expected. Impor-
tantly, TGF-b treatment has no effect on CD109 protein
levels in both SSc and normal skin fibroblasts (Figure 3,
top panel). The responsiveness of SSc and normal fibro-
blasts to exogenous TGF-b is demonstrated by their
increased fibronectin protein production (Figure 3, mid-
dle panel). Reprobing the membrane with an anti-b-
actin antibody confirms that equal amounts of protein
were loaded in each lane (Figure 3, bottom panel).
CD109 inhibits ECM and CCN2 protein production in SSc
and normal skin fibroblasts
It is well documented that SSc skin fibroblasts in culture
continue to express elevated levels of ECM proteins
such as fibronectin and collagen type I [15]. We there-
fore examined whether CD109 regulates levels of these
ECM proteins in SSc skin fibroblasts by blocking CD109
expression using siRNA, followed by western blot analy-
sis. Figure 4A shows that SSc skin fibroblasts transfected
with CD109-specific siRNA display a marked reduction
in CD109 protein level compared with control siRNA-
transfected cells, as expected (top panel). Importantly,
CD109 siRNA-transfected SSc skin fibroblasts display
elevated fibronectin, collagen type I and CCN2 protein
levels compared with control siRNA-transfected cells
(Figure 4A, middle panels). Reprobing the membrane
with an anti-b-actin (Figure 4A, bottom panel) antibody
confirms that equal amounts of protein were loaded in
each lane. Similar results are obtained using normal skin
fibroblasts (Figure 4B).
CD109 inhibits phosphorylation of Smad2 and Smad3 in
SSc and normal skin fibroblasts
We have previously shown that CD109 inhibits Smad2/3
phosphorylation in human keratinocytes and other cell
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types [37]. Because ECM and CCN2 proteins are regu-
lated by Smad-dependent mechanisms [27] we examined
whether CD109 regulates Smad2/3 phosphorylation in
SSc skin fibroblasts. Figure 4C shows that SSc skin
fibroblasts transfected with CD109 siRNA display ele-
vated Smad2 phosphorylation (top panel) and Smad3
phosphorylation (third panel) compared with control
siRNA-transfected cells. Total Smad2 (second panel)
and Smad3 (fourth panel) levels were not affected by
CD109 siRNA knockdown (Figure 4C, middle panels).
Reprobing the membrane with an anti-b-actin antibody
confirms that equal amounts of protein were loaded in
each lane (Figure 4C, bottom panel). Similar results
were obtained using normal skin fibroblasts (Figure 4D).
Although previous studies have reported elevated Smad2
and Smad3 phosphorylation in diffuse SSc fibroblasts
A 
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Figure 2 CD109 protein, but not mRNA, expression is increased in systemic sclerosis skin fibroblasts. (A) Cell lysates prepared from
systemic sclerosis (SSc) (in = 6, Patients S1 to S6) and normal (n = 4, controls N1 to N4) skin fibroblasts were analyzed by western blot using an
anti-CD109 antibody, as described in Materials and methods. The membrane was reprobed with an anti-b-actin antibody to confirm that equal
amounts of protein were loaded in each lane. (B) Densitometric analysis of CD109 protein levels (180 kDa band) in the cell lysates of SSc and
normal skin fibroblasts was performed using b-actin as a loading control. Results from two independent experiments corresponding to skin
fibroblasts from two different randomly selected groups of SSC patients versus normal subjects are shown: Experiment 1, normal (n = 4, controls
N1 to N4) and SSc (n = 7, Patients S1 to S7); Experiment 2, normal (n = 5, controls N5 to N9) and SSc (n = 9, Patients S8 to S16). P values
denote statistical differences of the means between normal and SSc fibroblasts using Student’s t test. (C) Data presented in (B) obtained from 16
SSc patients (nine with limited SSc and seven with diffuse SSc) and nine normal healthy controls were reorganized into normal control, limited
SSc and diffuse SSc groups and were reanalyzed. One data point (outlier) from the control group (value = 1.04) was removed. Fold-change in
the ratio of CD109/b actin in the limited SSc and diffuse SSc groups compared with normal controls is shown. One-way analysis of variance
analysis showed a statistically significant difference (P = 0.0127); Holm-Sidak analysis overall significance level = 0.05. Significant differences
observed are indicated. (D) Total RNA extracted from SSc (n = 7, Patients S1, S6, S8, S14, S7, S12 and S5) and normal (n = 7, controls N1 to N7)
skin fibroblasts was analyzed by RT-PCR using human CD109-specific (top panel) or GAPDH-specific (bottom panel) oligonucleotide primers. PCR
products were resolved by agarose gel (1.5%) electrophoresis and visualized by ethidium bromide staining. (E) Densitometric analysis of data
presented in (D) expressed as the ratio of CD109 PCR product to GAPDH internal control (CD109/GAPDH) is shown (P = 0.717).
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Figure 3 CD109 protein expression is not regulated by transforming growth factor beta in systemic sclerosis and normal fibroblasts.
Systemic sclerosis (SSc) and normal skin fibroblasts were treated for 24 hours with 0, 5, 10, 25, 50 and 100 pM transforming growth factor beta
1(TGF-b1) Cell lysates were prepared and analyzed by western blot using anti-CD109 (top panel) and anti-fibronectin (middle panel) antibodies.
The membrane was reprobed with an anti-b-actin antibody (bottom panel) to confirm that equal amounts of protein were loaded in each lane.









Figure 4 CD109 inhibits extracellular matrix protein production and Smad2/3 phosphorylation in systemic sclerosis and normal
fibroblasts. (A, C) Systemic sclerosis (SSc) skin fibroblasts and (B, D) normal skin fibroblasts were transiently transfected with CD109-specific
siRNA or control siRNA. Cell lysates were analyzed by western blot using (A, B) anti-CD109 (top panel), anti-fibronectin (second panel), anti-type I
collagen (third panel) or anti-CCN2 (fourth panel) antibodies or (C, D) anti-phosphoSmad2, anti-phosphoSmad3, anti-Smad2 or anti-Smad3
antibodies. Membranes were reprobed with an anti-b-actin (bottom panel) antibody to confirm that equal amounts of protein were loaded in
each lane. Results presented are representative of three independent experiments. The representative SSc fibroblast data shown correspond to
(A) SSc Patient S2 and (C) SSc Patient S16.
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[43,44], our results indicate that limited SSc and normal
skin fibroblasts have similar Smad2 and Smad3 phos-
phorylation levels (Figure 4C, D), which might be attrib-
uted to phenotypic differences in TGF-b pathway
activation between limited SSc and diffuse SSc skin
fibroblasts [45,46].
Soluble recombinant CD109 protein inhibits ECM and
CCN2 production in SSc fibroblasts
We have previously shown that CD109 is released from
the human keratinocyte cell surface [42], indicating that
endogenous CD109 exists as both membrane-tethered
and soluble forms. Our previous results also demon-
strate that endogenous CD109 protein released from the
cell surface and soluble recombinant CD109 protein
both bind TGF-b1 with high affinity and inhibit TGF-b1
binding to its signaling receptors ([42] and unpublished
observations, AB and AP, 2012). We therefore examined
whether soluble recombinant CD109 protein inhibits
TGF-b1-induced ECM and CCN2 protein production in
SSc fibroblasts. Figure 5A shows that TGF-b1 induces
fibronectin, collagen type I and CCN2 protein expres-
sion in SSc and normal skin fibroblasts as expected.
Importantly, addition of recombinant CD109 protein
leads to a marked reduction in TGF-b1-induced fibro-
nectin, collagen type I and CCN2 protein expression in
these cells. Reprobing the membrane with an anti-b-
actin antibody confirms that equal amounts of protein
were loaded in each lane (Figure 5A, bottom panel).
Densitometric analysis of data obtained from three dif-
ferent experiments confirms that addition of recombi-
nant CD109 protein results in a significant decrease in
the production of TGF-b1-induced fibronectin, collagen
type I and CCN2 in limited SSc and normal skin fibro-
blasts (Figure 5B). The results also indicate that limited
SSc skin fibroblasts display higher fibronectin and col-
lagen type I protein levels, but similar CCN2 levels,
compared with normal skin fibroblasts under basal
conditions.
Discussion
SSc is a rare connective tissue disease of unknown etiol-
ogy characterized by excessive ECM deposition in the
skin and internal organs [2,6,13]. Studies over the past
decade aimed at delineating the molecular mechanisms
involved in SSc fibrosis have identified TGF-b as a cen-
tral player and the TGF-b signaling pathway as an
important target for therapeutic intervention for SSc
[2,5,14]. We have previously identified CD109 as a TGF-
b co-receptor that inhibits TGF-b signaling in human
keratinocytes [37]. In the current study, we examine
CD109 expression and function in limited SSc and dif-
fuse SSc skin and normal skin in vivo, and in SSc and
normal dermal fibroblasts and epidermal keratinocytes
in vitro. Our results show that CD109 protein levels are
elevated in vivo in both the dermis and epidermis of SSc
skin compared with normal skin and in vitro in SSc der-
mal fibroblasts and epidermal keratinocytes compared
with normal fibroblasts and keratinocytes, respectively.
Although cultured SSc skin fibroblasts show higher
CD109 protein levels compared with normal skin fibro-
blasts, they do not appear to display elevated CD109
mRNA levels. Elevated CD109 protein levels were
observed in the skin tissue and fibroblasts from patients
with both limited SSc and diffuse SSc, suggesting that
increased CD109 protein expression might be a general
feature of SSc. We also demonstrate that treatment with
exogenous TGF-b1 does not alter CD109 protein levels
in SSc or normal skin fibroblasts, suggesting that CD109
is not a direct target of TGF-b in these cells. Moreover,
we found that CD109 inhibits ECM (fibronectin and
collagen type I) and CCN2 protein production in both
SSc and normal skin fibroblasts - as evidenced by the
findings that CD109 siRNA-transfected SSc and normal
skin fibroblasts display elevated fibronectin, collagen
type I and CCN2 protein levels, whereas treatment with
a recombinant CD109 protein leads to a decrease in
levels of these proteins. In addition, we show that
CD109 inhibits phosphorylation of Smad2 and Smad3 in
SSc and normal fibroblasts. Taken together, this study
identifies CD109 as a novel protein overexpressed in
limited SSc and diffuse SSc skin fibroblasts and indicates
that CD109 inhibits Smad2/3 signaling and ECM/CCN2
production in these cells, as in normal skin fibroblasts.
TGF-b co-receptors including endoglin, betaglycan
and CD109 are important regulators of TGF-b signaling,
and recent evidence indicates that they may modulate
fibrotic gene expression in SSc fibroblasts. Endoglin
expression has been reported to be higher in diffuse SSc
skin fibroblasts compared with normal fibroblasts, and
endoglin expression levels were shown to increase with
disease progression [47]. A more recent study demon-
strated that endoglin levels correlate with profibrotic
marker (collagen I and CCN2) levels in diffuse SSc skin
fibroblasts and that endoglin promotes profibrogenic
Smad1 signaling in these cells [48]. In addition, cell sur-
face endoglin and betaglycan expression levels were
shown to be increased in diffuse SSc skin fibroblasts
compared with normal fibroblasts and overexpression of
betaglycan was sufficient to promote basal and TGF-b-
induced CCN2 promoter activity in a mouse fibroblast
cell line (NIH3T3) [49]. Our results showing that
CD109 protein levels are elevated in both limited SSc
and diffuse SSc skin tissue and cultured fibroblasts com-
pared with controls suggest that upregulation of CD109
in these SSc subtypes may involve a common pathophy-
siological mechanism. Further studies to determine the
expression and function of TGF-b co-receptors in the
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different clinical subsets of SSc, in particular their rele-
vance to TGF-b-driven profibrogenic Smad1 signaling,
is an important avenue for future research.
An important question raised from our results is why
CD109 protein levels but not mRNA levels are increased
in SSc fibroblasts. Our data showing that the levels of
CD109 protein, but not of mRNA, are higher in limited
SSc and diffuse SSc skin fibroblasts compared with nor-
mal skin fibroblasts suggests that post-transcriptional
regulation of CD109 may be altered in limited SSc and
diffuse SSc skin. Such alteration may involve enhanced
CD109 protein synthesis and/or decreased CD109 pro-
tein degradation. Our preliminary results demonstrating
that CD109 protein degradation is impaired in SSc
fibroblasts (AB and AP, 2012, unpublished results) sug-
gest that impaired CD109 degradation may be responsi-
ble for the elevated CD109 protein levels in SSc
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Figure 5 Recombinant soluble CD109 protein inhibits transforming growth factor beta 1-induced extracellular matrix and CCN2
production. (A) Systemic sclerosis (SSc) and normal skin fibroblasts were left untreated (-) or treated (+) for 24 hours with 100 pM transforming
growth factor beta 1 (TGF-b1) in the presence of 1.0 nM recombinant CD109 protein or PBS/0.1% BSA vehicle control. Cell lysates were prepared
and analyzed by western blot using anti-fibronectin (top panel), anti-type I collagen (second panel) or anti-CCN2 (third panel) antibodies.
Membranes were reprobed with an anti-b-actin (bottom panel) antibody to confirm that equal amounts of protein were loaded in each lane.
Results presented are representative of three independent experiments. (B) Densitometric analysis of the data from the above blot was
performed using b-actin as a loading control. The representative SSc fibroblast data shown correspond to (A) SSc Patient S21 and (B) SSc
Patients S19, S2 and S16.
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several studies have reported increased TGF-b receptor
protein levels in SSc fibroblasts [21,50], leading to the
suggestion that TGF-b receptor stability is increased in
SSc due to impairment of TGF-b receptor degradation
[44]. Furthermore, recent microarray data [46,51] sup-
port our finding that CD109 mRNA levels in SSc and
normal fibroblasts are similar. However, quantitative
PCR analysis of RNA from a higher number of limited
SSc and diffuse SSc dermal fibroblasts with age-
matched, sex-matched and gender-matched control
samples will be required to confirm these results.
Paradoxically, despite the elevated CD109 protein levels
in SSc skin fibroblasts and the demonstrated ability of
endogenous CD109 protein to inhibit ECM and CCN2
production, the levels of ECM and CCN2 in SSc fibro-
blasts remain elevated. One possible explanation for these
results is that the upregulation of CD109 in SSc fibro-
blasts is not sufficient to completely counteract the acti-
vation of TGF-b or other profibrotic pathways in SSc.
This notion is supported by our finding that addition of a
recombinant CD109 protein to SSc fibroblasts, which
already express elevated CD109 protein levels, is still able
to decrease ECM and CCN2 levels. Whether the upregu-
lation of CD109 is an adaptive response or a consequence
of aberrant TGF-b signaling in SSc remains to be deter-
mined. Our results showing that CD109 is not a direct
target of TGF-b in SSc and normal skin fibroblasts sug-
gests that CD109 upregulation in SSc fibroblasts may
involve TGF-b-independent mechanisms.
The most promising finding in the current study is
that, despite the already upregulated CD109 protein
expression in SSc, the addition of further exogenous
CD109 is able to downregulate ECM production. Aber-
rant activation of autocrine TGF-b signaling is a critical
factor involved in the maintenance of the fibrotic phe-
notype of SSc fibroblasts [16]. Identifying factors that
inhibit TGF-b signaling in fibroblasts may thus lead to
the development of novel anti-TGF-b therapies for the
treatment of SSc. Our results showing that CD109
siRNA transfection leads to a marked increase, and that
addition of recombinant CD109 protein results in a sig-
nificant decrease, in the production of fibronectin, col-
lagen type I and CCN2 in both SSc and normal skin
fibroblasts suggest that CD109 has potent antifibrotic
effects in these cells. In addition, our finding that
CD109 siRNA knockdown in SSc and normal skin fibro-
blasts is associated with enhanced Smad2/3 phosphory-
lation suggests that endogenous CD109 inhibits
autocrine TGF-b signaling in these cells. These results
suggest that mechanism by which CD109 decreases
ECM and CCN2 production in SSc and normal skin
fibroblasts may involve inhibition of Smad2/3 phosphor-
ylation. Together, our results suggest that recombinant
CD109 protein is a promising candidate for antifibrotic
therapy in SSc.
In addition to playing a possible pathophysiological
role in SSc, the elevated CD109 protein levels may serve
as a biomarker of disease activity in SSc. CD109 is a
member of the a2-macroglobulin/complement family of
thioester-containing proteins and has been shown to be
expressed in endothelial cells, platelets and activated T
cells [28,29]. Recent studies have shown that CD109 is
differentially expressed in a variety of human tumors
[30-34,37,52,53], leading to the suggestion that CD109
may represent a novel biomarker for certain cancers.
The relatively small number of samples examined in the
current study does not allow us to correlate CD109
expression levels with disease severity and/or duration.
More work is needed to determine whether CD109
levels are differentially expressed at specific phases of
disease activity in limited SSC and diffuse SSc.
Conclusions
Despite the findings that CD109 is upregulated in SSc
skin and cultured SSc skin fibroblasts, and that blocking
CD109 expression in SSc cells leads to further produc-
tion of ECM, it is clear that the CD109 response in SSc
is insufficient to inhibit the production of excess ECM.
Importantly, however, exposure of SSc fibroblasts to
additional exogenous CD109 does result in the downre-
gulation of excess ECM production - it is therefore
worthwhile pursuing the role of CD109 as an antifibro-
tic agent and exploring whether CD109 protein expres-
sion represents a biomarker for active disease in SSc.
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